Drugs that contain Glycopyrrolate; Indacaterol Maleate

1. List of Utibron drug patents

UTIBRON's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(5 years from now)

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

UTIBRON family patents

15

United States

12

United Kingdom

9

European Union

8

Japan

6

China

5

Canada

5

Australia

3

Brazil

3

Spain

3

New Zealand

3

Norway

3

Russia

2

Poland

2

Slovenia

2

Korea, Republic of

2

Hong Kong

2

Cyprus

2

Denmark

2

South Africa

2

Austria

2

Portugal

2

Singapore

1

Taiwan

1

Morocco

1

Germany

1

Malaysia

1

Argentina

1

Mexico

1

Ecuador

1

Tunisia

1

Israel

1

Peru

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic